MIMEDX Announced the Launch of HELIOGENTM Fibrillar Collagen Matrix
On July 31, 2024, MiMedx Group, Inc. launched HELIOGEN™ Fibrillar Collagen Matrix, a particulate xenograft product designed to treat complex wounds, especially in surgical environments. HELIOGEN is a shelf-stable product that contains Type I and Type III collagen, closely resembling the natural structure of connective tissue.
“We are pleased to introduce our first xenograft option and 510(k) cleared product to complement our leading placental-based solutions in the surgical market,” stated Joseph H. Capper, MIMEDX Chief Executive Officer. “As we have been messaging, one of our strategic i...